Sanofi and Kowa pick up rights to Chugai's SGLT2 inhibitor in crowded Japan market
This article was originally published in Scrip
Executive Summary
Given that the molecule was its only pipeline project in diabetes, it is no surprise that Chugai has decided to license out the Japanese rights to the sodium-glucose co-transporter 2 (SGLT2) inhibitor tofogliflozin (CSG452).